Pharmaceutical drug companies have developed therapeutics to target the JAK-STAT pathway for treatment of RA, primarily comprising of JAK inhibitors, also known as JAKi (Fragoulis et al., 2019). Here, SOAT1 is linked to rheumatoid arthritis.